Keitaro Shimozaki

Our single-center retrospective study revealed a significant tendency associating the development of multiple irAEs with favorable prognoses.

Since pembrolizumab, an anti-programmed death-1 (PD-1) antibody, showed a dramatic response to immunogenic cancers with microsatellite instability-high (MSI-H) and/or deficient mismatch repair (dMMR) in the pilot clinical trial KEYNOTE-016, subsequent studies have confirmed durable responses of anti-PD-1 inhibitors for MSI-H/dMMR solid tumors. As immunotherapy is described as a "game changer," the therapeutic landscape for MSI-H/dMMR solid tumors including gastrointestinal cancers has changed co

The aim of this study was to determine the risk factors for immune-related adverse events (irAEs) induced by immune checkpoint inhibitors. The authors conducted a retrospective study in which patients with malignant melanoma, non-small-cell lung cancer, gastric cancer or renal cell carcinoma who received anti-PD-1/PD-L1 antibodies were included. Of 247 patients, 118 developed a total of 182 irAEs. In the multivariate Fine-Gray regression analysis, serum albumin level ≥3.6 g/dl (hazard ratio: 1.6

Therapeutic developments in the targeting of human epidermal growth factor receptor 2 (HER2)-expressing gastric cancer have followed the dramatic success of HER2-expressing breast cancer treatment, which has facilitated the expansion of indications for anti-HER2 agents to include not only conventional HER2-positive breast cancer, but also HER2-low and HER2-ultralow subgroups. The targetability of HER2-low gastric cancer, however, has yet to be established. Hence, further studies are needed to co

The modified JCOG prognostic index showed excellent stratification of overall survival in real-world patients, which could also help determine the need for treatment changes throughout the continuum of chemotherapy.

First-line zolbetuximab plus chemotherapy was safely introduced to real-world patients with claudin 18.2-positive AGC, with effective management of nausea and vomiting, applicable in clinical practice.

<title>Abstract</title> Background Immune checkpoint inhibitors have been approved for various types of cancer; however, they cause a broad spectrum of immune-related adverse events (irAEs). The association between the development of irAEs and the clinical benefit remains uncertain. We aimed to evaluate the association of irAEs and the treatment efficacy in the real-world practice. Methods We conducted a retrospective study on patients with recurrent or metastatic non-small cell lung cancer, mel

T-DXd and nivolumab showed distinct efficacy and toxicity profiles as ≥ third line treatments for HER2-positive AGC. Considering the distinct features of each regimen, they may help clinicians personalize optimal treatment approaches for these patients.

First-line nivolumab plus chemotherapy provides benefits to real-world patients with HER2-negative AGC and implies that the rapidity and magnitude of tumor shrinkage may have a significant impact on the duration of survival.

CCE-2 might be a safe and useful entire intestinal tract screening method for the early detection of ICI-induced enterocolitis in patients with malignancies.

Triplet therapy had no survival benefit versus doublet therapy in the overall and IPTW cohorts or specific subgroups for real-world patients with BRAF^V600E mutant mCRC.

<h3>Background</h3> Despite several studies highlighting the importance of zolbetuximab-induced gastrointestinal toxicity, the incidence of and risk factors for severe hypoalbuminemia during zolbetuximab plus chemotherapy for the treatment of claudin 18.2-positive advanced gastric cancer have not been fully elucidated. <h3>Materials and methods</h3> We retrospectively evaluated 29 patients (median age, 62 years; men, 45%; diffuse-type histology, 76%; prior total gastrectomy, 24%). Severe hypoalb

37 Background: The survival benefit of FOLFOXIRI plus bevacizumab (Triplet) over Doublet in patients (pts) with BRAF V600E -mutant metastatic colorectal cancer (mCRC) remains controversial. We compared Triplet therapy with Doublet and explored the pts subgroups that could benefit from intensive chemotherapy (chemo) using real-world data. Methods: WJOG13219G was a multicenter, retrospective registry-based study of pts with BRAF V600E -mutant mCRC who received first-line doublet or triplet chemo w

Fish bones are the leading type of gastrointestinal foreign body in Japan, and most require surgical removal. We describe the endoscopic removal of fish bones from the gastrointestinal tracts of two patients. Case 1 : A 70-year-old man presented with pain in the left lower abdomen. A 3-cm linear, high-density foreign body was identified by CT in the sigmoid colon. A fish bone was removed by colonoscopy. Case 2 : A 49-year-old woman was referred to our institution with upper abdominal pain. A lin